Have you lost money investing in Fulgent Genetics? If yes, please visit us Fulgent Genetics, Inc. Stockholder Class Action or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.

NEW YORK, Nov. 15, 2022 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP, a nationally recognized investor rights law firm, is reminding investors of the deadline for filing a motion by lead plaintiff in a securities class action lawsuit filed on behalf of investors, who have between purchased or acquired the securities of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California alleging violations of the Securities Exchange Act of 1934.

Fulgent, along with its subsidiaries, provides COVID-19, molecular diagnostics and genetic testing services to physicians and patients in the United States and internationally. Fulgent must comply with the federal anti-kickback statute, which prohibits knowingly and intentionally paying “compensations” to induce or reward patient referrals, or generating business for items or services provided by federal and federal healthcare programs Stark Law prohibits a physician from referring certain designated health care services, including laboratory services, covered by the Medicare program to an entity with which the physician or immediate family member has a direct or indirect financial relationship.

Plaintiff alleges that throughout the Class Period, Defendants made materially false and misleading statements. Specifically, Plaintiff alleges that Defendants failed to disclose: (i) Fulgent conducted medically unnecessary laboratory testing and engaged in improper billing practices related to laboratory testing…